Ndibazza 2012

Methods	RCT Length of follow‐up: 5 years
Participants	All children living in endemic area Number analysed for primary outcome: 1423 Mean age: 15 months (randomized at 1.5 years) Inclusion criteria: 15 month old children whose mothers participated in the pregnancy phase of the trial (pregnant healthy women from the area, planning to deliver at Entebbe Hospital) Exclusion criteria: none stated
Interventions	Multiple dose vs placebo Factorial designa Albendazole: 200 mg quarterly from age 15 to 21 months; 400 mg quarterly from age 2 to 5 years; Matching placebo. aMothers when pregnant had been randomized in a 1:1:1:1 ratio to receive single‐dose albendazole (400 mg) + praziquantel (40 mcg/kg), albendazole + praziquantel placebo, albendazole placebo + praziquantel, or albendazole placebo + praziquantel placebo.
Outcomes	Weight‐for‐age z‐score; Height‐for‐age z‐score; Weight‐for‐height z‐score; Haemoglobin; Cognitive tests including Block design, Picture vocabulary scale, Sentence repetition, Verbal fluency, Counting span, Running memory, Picture search, Wisconsin card sort test, Tap once tap twice task, Shapes task, Tower of London; Serious adverse events; Death. Not included in review: immune response at age 5 years to BCG and tetanus immunisation, incidence of malaria, diarrhoea, pneumonia, measles, and tuberculosis, measures of fine motor function and gross motor function.
Notes	Location: Entebbe, Uganda Community category: 3 Source of funding: Wellcome Trust
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Randomization code generated by statistician using Stata version 7.
Allocation concealment (selection bias)	Unclear risk	No details reported.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Participants and provider blinded. Not reported for assessors.
Incomplete outcome data (attrition bias) All outcomes	High risk	Inclusion of all randomized participants (number evaluable/number randomized): 71% (1423/2016) of randomized participants.
Selective reporting (reporting bias)	High risk	Serious adverse events not reported.
Other bias	Low risk	No other obvious source of bias.